Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 495,422
  • Shares Outstanding, K 56,298
  • Annual Sales, $ 23,610 K
  • Annual Income, $ -105,510 K
  • EBIT $ -24 M
  • EBITDA $ -18 M
  • 60-Month Beta 0.99
  • Price/Sales 5.84
  • Price/Cash Flow N/A
  • Price/Book 3.75

Options Overview Details

View History
  • Implied Volatility 226.06% (+14.58%)
  • Historical Volatility 38.51%
  • IV Percentile 98%
  • IV Rank 69.15%
  • IV High 304.21% on 11/14/25
  • IV Low 50.87% on 05/22/25
  • Expected Move (DTE 25) 1.39 (15.84%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 385
  • Volume Avg (30-Day) 766
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 47,543
  • Open Int (30-Day) 44,081
  • Expected Range 7.41 to 10.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.05
  • Number of Estimates 3
  • High Estimate 0.07
  • Low Estimate 0.02
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +107.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.25 +6.67%
on 02/11/26
9.62 -8.52%
on 02/03/26
-0.22 (-2.44%)
since 01/20/26
3-Month
8.01 +9.86%
on 12/19/25
9.62 -8.52%
on 02/03/26
-0.25 (-2.76%)
since 11/20/25
52-Week
6.19 +42.16%
on 04/09/25
13.16 -33.13%
on 07/15/25
+0.97 (+12.39%)
since 02/20/25

Most Recent Stories

More News
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevra’s executive officers and whether investor...

ZVRA : 8.80 (-1.01%)
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.80 (-1.01%)
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.80 (-1.01%)
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™

Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD Company to host satellite symposium...

ZVRA : 8.80 (-1.01%)
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference

CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.80 (-1.01%)
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)

CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.80 (-1.01%)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.80 (-1.01%)
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.80 (-1.01%)
Zevra Therapeutics, Inc. Announces CFO Transition

CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.80 (-1.01%)
Zevra Therapeutics: Q3 Earnings Snapshot

Zevra Therapeutics: Q3 Earnings Snapshot

ZVRA : 8.80 (-1.01%)

Business Summary

Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. Zevra Therapeutics, formerly known as KemPharm Inc., is based in CELEBRATION, Fla.

See More

Key Turning Points

3rd Resistance Point 9.25
2nd Resistance Point 9.14
1st Resistance Point 8.97
Last Price 8.80
1st Support Level 8.69
2nd Support Level 8.58
3rd Support Level 8.41

See More

52-Week High 13.16
Fibonacci 61.8% 10.50
Fibonacci 50% 9.68
Fibonacci 38.2% 8.85
Last Price 8.80
52-Week Low 6.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar